GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rein Therapeutics Inc (NAS:RNTX) » Definitions » 6-1 Month Momentum %

RNTX (Rein Therapeutics) 6-1 Month Momentum % : -21.83% (As of Mar. 03, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rein Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-03), Rein Therapeutics's 6-1 Month Momentum % is -21.83%.

The industry rank for Rein Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

RNTX's 6-1 Month Momentum % is ranked worse than
62.69% of 1474 companies
in the Biotechnology industry
Industry Median: -11.76 vs RNTX: -21.83

Competitive Comparison of Rein Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Rein Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rein Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's 6-1 Month Momentum % falls into.



Rein Therapeutics  (NAS:RNTX) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rein Therapeutics  (NAS:RNTX) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Rein Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Rein Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rein Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
12407 N. Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.
Executives
James Brian Windsor officer: See Remarks 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey director C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso director FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler officer: See Remarks 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros director C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H director C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic officer: SVP, Chief Medical Officer C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory officer: SVP, Chief Business Officer 305 THAYER POND ROAD, WILTON CT 06897
William Mckee director
Nolan Howard Sigal director 941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall officer: VP, Finance and Operations C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd officer: President and CEO 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121